AAPL340.08+3.17 (+0.94%) ▲|ABBV263.20+6.29 (+2.45%) ▲|ABT107.27+2.78 (+2.66%) ▲|ACN164.66+10.60 (+6.88%) ▲|ADBE249.18+11.43 (+4.81%) ▲|AMAT476.46-40.43 (-7.82%) ▼|AMD454.62-40.33 (-8.15%) ▼|AMGN393.10+16.84 (+4.48%) ▲|AMT171.50+4.76 (+2.85%) ▲|AMZN230.86-0.53 (-0.23%) ▼|AVGO380.91-2.31 (-0.60%) ▼|AXP336.63+1.24 (+0.37%) ▲|BA221.56+10.06 (+4.76%) ▲|BAC62.62+0.49 (+0.79%) ▲|BKNG199.31+12.52 (+6.70%) ▲|BLK1,097.55+35.41 (+3.33%) ▲|BMY63.60+1.04 (+1.66%) ▲|BNY156.49-1.28 (-0.81%) ▼|BRK-B512.37+15.19 (+3.06%) ▲|C132.47-0.63 (-0.47%) ▼|CAT840.85-32.43 (-3.71%) ▼|CL92.73+0.75 (+0.82%) ▲|CMCSA24.19+1.39 (+6.10%) ▲|COF212.41+5.36 (+2.59%) ▲|COP114.10-1.48 (-1.28%) ▼|COST966.58+15.00 (+1.58%) ▲|CRM181.50+7.90 (+4.55%) ▲|CSCO115.58+1.01 (+0.88%) ▲|CVS109.34+2.27 (+2.12%) ▲|CVX187.58-2.42 (-1.27%) ▼|DE639.84+14.82 (+2.37%) ▲|DHR199.05+2.55 (+1.30%) ▲|DIS98.89+2.24 (+2.32%) ▲|DUK129.24+0.41 (+0.32%) ▲|EMR151.81+2.51 (+1.68%) ▲|FDX312.64+1.85 (+0.60%) ▲|GD393.19+4.05 (+1.04%) ▲|GE363.59+1.98 (+0.55%) ▲|GEV943.38-53.19 (-5.34%) ▼|GILD134.32+3.80 (+2.91%) ▲|GM90.30+3.26 (+3.75%) ▲|GOOG332.60+6.03 (+1.85%) ▲|GOOGL333.71+7.15 (+2.19%) ▲|GS1,033.34-14.89 (-1.42%) ▼|HD344.47+8.38 (+2.49%) ▲|HON247.05+1.30 (+0.53%) ▲|IBM227.55+11.27 (+5.21%) ▲|INTC86.30-5.37 (-5.86%) ▼|INTU312.99+9.08 (+2.99%) ▲|ISRG361.80+4.97 (+1.39%) ▲|JNJ266.73+0.78 (+0.29%) ▲|JPM357.31+1.11 (+0.31%) ▲|KO88.27+4.20 (+5.00%) ▲|LIN511.18+4.16 (+0.82%) ▲|LLY1,220.66+23.13 (+1.93%) ▲|LMT581.31+1.31 (+0.23%) ▲|LOW218.24+6.69 (+3.16%) ▲|LRCX269.61-22.00 (-7.54%) ▼|MA562.75+11.04 (+2.00%) ▲|MCD273.02+2.35 (+0.87%) ▲|MDLZ62.48+1.81 (+2.98%) ▲|MDT86.88+2.66 (+3.16%) ▲|META593.41-0.46 (-0.08%) ▼|MMM182.48+4.25 (+2.38%) ▲|MO74.82+1.93 (+2.65%) ▲|MRK131.82+1.06 (+0.81%) ▲|MS211.58-2.98 (-1.39%) ▼|MSFT393.35+4.25 (+1.09%) ▲|MU820.53-79.67 (-8.85%) ▼|NEE89.28+0.45 (+0.51%) ▲|NFLX72.39+1.99 (+2.83%) ▲|NKE43.05+0.91 (+2.16%) ▲|NOW110.62+5.06 (+4.79%) ▲|NVDA197.01+0.50 (+0.25%) ▲|ORCL119.96+0.06 (+0.05%) ▲|PEP142.86+3.07 (+2.20%) ▲|PFE25.25+0.58 (+2.35%) ▲|PG148.88+0.25 (+0.17%) ▲|PLTR123.53-8.00 (-6.08%) ▼|PM200.17+4.51 (+2.31%) ▲|QCOM162.88-7.16 (-4.21%) ▼|RTX218.58+0.16 (+0.07%) ▲|SBUX103.10-0.55 (-0.53%) ▼|SCHW105.97+1.79 (+1.72%) ▲|SO96.78+0.30 (+0.31%) ▲|SPG236.70+5.03 (+2.17%) ▲|T24.66+0.24 (+0.98%) ▲|TMO576.41+16.88 (+3.02%) ▲|TMUS182.39+5.18 (+2.92%) ▲|TSLA307.44-1.78 (-0.58%) ▼|TXN277.07-2.34 (-0.84%) ▼|UBER70.74+2.56 (+3.75%) ▲|UNH428.79+11.15 (+2.67%) ▲|UNP294.45-4.85 (-1.62%) ▼|UPS105.53-7.42 (-6.57%) ▼|USB64.43+0.94 (+1.48%) ▲|V366.59+4.06 (+1.12%) ▲|VZ48.19+0.87 (+1.84%) ▲|WFC86.87-0.40 (-0.46%) ▼|WMT113.10+1.36 (+1.22%) ▲|XOM153.04-1.73 (-1.12%) ▼|AAPL340.08+3.17 (+0.94%) ▲|ABBV263.20+6.29 (+2.45%) ▲|ABT107.27+2.78 (+2.66%) ▲|ACN164.66+10.60 (+6.88%) ▲|ADBE249.18+11.43 (+4.81%) ▲|AMAT476.46-40.43 (-7.82%) ▼|AMD454.62-40.33 (-8.15%) ▼|AMGN393.10+16.84 (+4.48%) ▲|AMT171.50+4.76 (+2.85%) ▲|AMZN230.86-0.53 (-0.23%) ▼|AVGO380.91-2.31 (-0.60%) ▼|AXP336.63+1.24 (+0.37%) ▲|BA221.56+10.06 (+4.76%) ▲|BAC62.62+0.49 (+0.79%) ▲|BKNG199.31+12.52 (+6.70%) ▲|BLK1,097.55+35.41 (+3.33%) ▲|BMY63.60+1.04 (+1.66%) ▲|BNY156.49-1.28 (-0.81%) ▼|BRK-B512.37+15.19 (+3.06%) ▲|C132.47-0.63 (-0.47%) ▼|CAT840.85-32.43 (-3.71%) ▼|CL92.73+0.75 (+0.82%) ▲|CMCSA24.19+1.39 (+6.10%) ▲|COF212.41+5.36 (+2.59%) ▲|COP114.10-1.48 (-1.28%) ▼|COST966.58+15.00 (+1.58%) ▲|CRM181.50+7.90 (+4.55%) ▲|CSCO115.58+1.01 (+0.88%) ▲|CVS109.34+2.27 (+2.12%) ▲|CVX187.58-2.42 (-1.27%) ▼|DE639.84+14.82 (+2.37%) ▲|DHR199.05+2.55 (+1.30%) ▲|DIS98.89+2.24 (+2.32%) ▲|DUK129.24+0.41 (+0.32%) ▲|EMR151.81+2.51 (+1.68%) ▲|FDX312.64+1.85 (+0.60%) ▲|GD393.19+4.05 (+1.04%) ▲|GE363.59+1.98 (+0.55%) ▲|GEV943.38-53.19 (-5.34%) ▼|GILD134.32+3.80 (+2.91%) ▲|GM90.30+3.26 (+3.75%) ▲|GOOG332.60+6.03 (+1.85%) ▲|GOOGL333.71+7.15 (+2.19%) ▲|GS1,033.34-14.89 (-1.42%) ▼|HD344.47+8.38 (+2.49%) ▲|HON247.05+1.30 (+0.53%) ▲|IBM227.55+11.27 (+5.21%) ▲|INTC86.30-5.37 (-5.86%) ▼|INTU312.99+9.08 (+2.99%) ▲|ISRG361.80+4.97 (+1.39%) ▲|JNJ266.73+0.78 (+0.29%) ▲|JPM357.31+1.11 (+0.31%) ▲|KO88.27+4.20 (+5.00%) ▲|LIN511.18+4.16 (+0.82%) ▲|LLY1,220.66+23.13 (+1.93%) ▲|LMT581.31+1.31 (+0.23%) ▲|LOW218.24+6.69 (+3.16%) ▲|LRCX269.61-22.00 (-7.54%) ▼|MA562.75+11.04 (+2.00%) ▲|MCD273.02+2.35 (+0.87%) ▲|MDLZ62.48+1.81 (+2.98%) ▲|MDT86.88+2.66 (+3.16%) ▲|META593.41-0.46 (-0.08%) ▼|MMM182.48+4.25 (+2.38%) ▲|MO74.82+1.93 (+2.65%) ▲|MRK131.82+1.06 (+0.81%) ▲|MS211.58-2.98 (-1.39%) ▼|MSFT393.35+4.25 (+1.09%) ▲|MU820.53-79.67 (-8.85%) ▼|NEE89.28+0.45 (+0.51%) ▲|NFLX72.39+1.99 (+2.83%) ▲|NKE43.05+0.91 (+2.16%) ▲|NOW110.62+5.06 (+4.79%) ▲|NVDA197.01+0.50 (+0.25%) ▲|ORCL119.96+0.06 (+0.05%) ▲|PEP142.86+3.07 (+2.20%) ▲|PFE25.25+0.58 (+2.35%) ▲|PG148.88+0.25 (+0.17%) ▲|PLTR123.53-8.00 (-6.08%) ▼|PM200.17+4.51 (+2.31%) ▲|QCOM162.88-7.16 (-4.21%) ▼|RTX218.58+0.16 (+0.07%) ▲|SBUX103.10-0.55 (-0.53%) ▼|SCHW105.97+1.79 (+1.72%) ▲|SO96.78+0.30 (+0.31%) ▲|SPG236.70+5.03 (+2.17%) ▲|T24.66+0.24 (+0.98%) ▲|TMO576.41+16.88 (+3.02%) ▲|TMUS182.39+5.18 (+2.92%) ▲|TSLA307.44-1.78 (-0.58%) ▼|TXN277.07-2.34 (-0.84%) ▼|UBER70.74+2.56 (+3.75%) ▲|UNH428.79+11.15 (+2.67%) ▲|UNP294.45-4.85 (-1.62%) ▼|UPS105.53-7.42 (-6.57%) ▼|USB64.43+0.94 (+1.48%) ▲|V366.59+4.06 (+1.12%) ▲|VZ48.19+0.87 (+1.84%) ▲|WFC86.87-0.40 (-0.46%) ▼|WMT113.10+1.36 (+1.22%) ▲|XOM153.04-1.73 (-1.12%) ▼|
24 C
New York
Wednesday, July 29, 2026

Tag: pharmaceutical

newssourceFORcompanyinformationcontent1releasesmarket

Halper Sadeh LLC is Investigating Whether LPRO, NUVL, OGN, SUNE are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

RRS® HA Long Lasting awarded Best Injectable in Skin Revitalization at AMWC 2026, reinforcing Skin Tech Pharma Group’s leadership in the Skin Builder category

BARCELONA, Spain, June 17, 2026 /PRNewswire/ -- Skin Tech Pharma Group proudly announces that its flagship injectable, RRS® HA LONG LASTING, has been recognized...

VoIP-Pal.com Inc. Engages Veteran Consumer Class Action and Complex Litigation Attorney C. Glen Ged as Strategic Legal Consultant

VoIP-Pal Engages Nationally Recognized Class Action Attorney C. Glen Ged

[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends,...

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global GLP-1 Receptor Agonist Market size & share revenue was valued at approximately USD 28.7 Billion in 2025 and is expected to reach USD 34.2 Billion in 2026 and is expected to reach around USD 95.3 Billion by 2035, at a CAGR of 12.1% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Pfizer Inc., Merck & Co. Inc., Zealand Pharma A/S, Hanmi Pharmaceutical Co. Ltd. and others. 
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global GLP-1 Receptor Agonist Market size & share revenue was valued at approximately USD 28.7 Billion in 2025 and is expected to reach USD 34.2 Billion in 2026 and is expected to reach around USD 95.3 Billion by 2035, at a CAGR of 12.1% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Pfizer Inc., Merck & Co. Inc., Zealand Pharma A/S, Hanmi Pharmaceutical Co. Ltd. and others.

The Quiet Bottleneck in AI Drug Discovery Isn’t the Model — It’s the Biology Underneath It

Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize...

DuPont to Unveil New Tyvek® Innovation at Safe@Work 2026 in Thailand

New Tyvek® innovation designed to support worker safety and comfort across ASEANBANGKOK, June 16, 2026 /PRNewswire/ -- DuPont (NYSE: DD) today announced that it...

Minghui Pharmaceutical Presents Compelling Phase I/II Results for MHB018A, a Novel Subcutaneous Anti-IGF-1R Antibody for Thyroid Eye Disease, in an Oral Presentation at ENDO...

MHB018A demonstrated outstanding clinical activity in both active and chronic thyroid eye diseaseAt 450 mg Q4W, MHB018A achieved a remarkable 81% proptosis response at...

Laboratory Filtration Market Eyes US$ 6.8 Bn by 2030: Latest Report by Wissen Research

SHERIDAN, Wyo., June 15, 2026 /PRNewswire/ -- The global laboratory filtration market is projected to grow from USD 4.5 billion in 2025 to USD...

Four Rubin Rudman Partners Named to 2026 Lawdragon 500 X – The Next Generation

BOSTON, June 15, 2026 /PRNewswire/ -- Rubin Rudman is pleased to announce that partners Allison Collins, Lauren DeMatteo, Steven DiCairano, and Laura Kirshenbaum have...

Stem Cell Therapy Market worth $3.65 billion by 2035 | MarketsandMarkets™

DELRAY BEACH, Fla., June 15, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Stem Cell Therapy Market is projected to grow from about USD 0.48 billion...

Companion Diagnostics Market worth $11.57 billion by 2031 | MarketsandMarkets™

DELRAY BEACH, Fla., June 15, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Companion Diagnostics Market is projected to grow from about USD 6.31 billion in...

Process Industries Converge in Houston for Inaugural ChemE Show 2026 Powered by ACHEMA

Two days of main stage programming, technical sessions, and hands-on technology evaluation drew engineers, plant managers, and decision-makers from across the chemicals, pharmaceutical, and...

Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway

New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker’s protective barrier function

ENA Respiratory Receives USPTO Notice of Allowance for Two Patents Covering TLR2 Agonists and Rhinovirus-Mediated COPD Exacerbations

MELBOURNE, Australia, June 15, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for two patent applications, notably a composition-of-matter patent and method-of-use for its Toll-like receptor 2 (TLR2) therapies.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPharmaceutical

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers